Previous reports have shown that autoantibodies against AT1 receptors (AT1-AA; AT1 agonists) and for ACE2 (ACE2-AA, ACE2 antagonist) contribute to enhance the pro-inflammatory RAS axis (20), and in a previous study we observed significant association between AT1-AA, ACE2-AA and severity of COVID-19 outcome, suggesting that these autoantibodies could be used as an index of progression of COVID-19 toward severity (16). Here, ACE2 is linked to COVID-19.